Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.57 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | ALDH1A3 | P47895 | 5/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13645995 | 0.94 | CYP2A6 (0.64) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL1825553 | 0.89 | CYP2A6 (0.53) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL12201470 | 0.86 | CYP2A6 (0.55) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL13645975 | 0.86 | CYP2A6 (0.59) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL6384525 | 0.85 | ALDH1A1 (0.55) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL12201383 | 0.84 | ALDH1A1 (0.59) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL10892510 | 0.84 | CYP2A6 (0.57) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL3302551 | 0.82 | CYP2A6 (0.55) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL20861927 | 0.82 | CYP2A6 (0.55) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL21124408 | 0.82 | CYP2A6 (0.55) | CYP2A6CYP2A13ALDH1A1ALDH1A3ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239923-A | Compounds useful as inhibitors of factor XIIa, pharmaceutical compositions and uses thereof | 合肥工业大学 | 2024-06-25 | — | — | CN | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| EP-2488519-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PF MEDICAMENT (FR) | 2015-06-10 | — | — | EP | disclosed |
| US-8889711-B2 | Pyrazolopyridine derivatives as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-11-18 | — | — | US | disclosed |
| US-8889711-B2 | Pyrazolopyridine derivatives as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-11-18 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20060235073-A1 | Diamino-functional chalcones | LICA PHARMACEUTICALS A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| EP-1506158-A2 | DIAMINO-FUNCTIONAL CHALCONES | Lica Pharmaceuticals A/S (DK) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097576-A2 | DIAMINO-FUNCTIONAL CHALCONES | LICA PHARMACEUTICALS A/S (DK) | 2003-11-27 | — | — | WO | disclosed |
| US-5378705-A | Skin disorders, antiaging agents and antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-01-03 | — | — | US | disclosed |
| US-5250562-A | Skin disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5106981-A | Skin disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-04-21 | — | — | US | disclosed |
| US-4940707-A | Stilbene derivatives for treatment of skin disorders | HOFFMAN-LA ROCHE INC. (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0331983-A2 | Stilbene derivatives, their preparation and their use in medicines | F. HOFFMANN-LA ROCHE AG (CH) | 1989-09-13 | — | — | EP | disclosed |
| CN-1035500-A | STILBENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1989-09-13 | — | — | CN | disclosed |
| US-4369310-A | PHOTOGRAPHIC DYES | CIBA-GEIGY LTD. (CH) | 1983-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | DPYD, TYMP, ABCB1 | CYP2A6 741/4885CYP2A13 1402/4885ALDH1A1 170/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | CYP2A6 1978/4885CYP2A13 2444/4885ALDH1A1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.